Red to Green🚦— Just Like That!
Don't miss Paul's crypto video! 📺
Note: Please read our disclaimer at the bottom of the article.
#StrongHands 🙌 #BOP 🚀 Nation Update ️️️️️️️️️️️️️️️️️️️❤️️
Hi, I’m Paul Mampilly.
Welcome to my company's Substack, where we provide daily coverage of #OGI (opportunity, growth, and innovation) market trends, macro level analysis, and stock picks.
Like our name suggests, at ATG Digital, we go Against the Grain to support everyday people on their investing journeys.
ATG also represents seeing the world for what is abundantly clear to see — an opportunity for incredible growth and the BRIGHT and PROSPEROUS future that lies ahead.
To aid you on your journey to financial freedom, we have five paid plans starting at $9.99 for you to consider.
With a subscription you get:
Premium Content: Weekly market and stock updates via email newsletter.
Stock Picking Guidance: Flash (buy/sell) alerts with targeted price points.
Model Portfolio Access: Access to LIVE portfolios.
Webinars: Private events with the team based on ideas preselected by you. (Purple Tier Members)
Just visit atgdigital.media to see which plan is the best fit for your journey!
Substack 🥞 subscribers: 6,001 (+7)
Dan: 1 Stock Hits a Bullseye 🎯 — 20% Jump!
Watching our positions turn from red to green — there’s truly nothing quite like it!
A reversal is becoming more evident as biotech continues to lead the bull market.
Many companies in this sector are up, and we believe the trend points to even higher gains!
That’s why we’ve filled our ATG Digital model portfolios with biotech companies!
Let’s look at one that was up 20% yesterday . . .
Small Cap, Huge Ambitions 💪
Esperion Therapeutics Inc. (Nasdaq: ESPR) is a biopharmaceutical company focused on developing and commercializing oral, small-molecule therapies for lowering cholesterol levels.
These specifically target patients who can’t tolerate or don’t respond adequately to statins.
Yesterday, ESPR announced that it filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET — once-daily, accessible, oral non-statin medications that reduce cholesterol and cardiovascular risk.
Heart disease is the second leading cause of death in Canada, killing 14 people every hour.
It also accounts for one in three deaths in the U.S. and Europe.
The CEO of ESPR, Sheldon Koenig, said:
“These submissions mark another pivotal milestone towards bringing our potentially lifesaving medications to the millions of patients around the world who need it.”
The company’s NEXLETOL and NEXLIZET drugs are covered by more than 90% of commercial plans and many Medicare plans.
This helped revenue grow!
Scaling New Growth 📈
Last quarter, ESPR saw revenue increase 52% year over year (YoY) to $51.6 million.
In the month of October alone, total retail prescriptions increased 17% YoY.
This leads us to believe revenue is growing with plenty of runway ahead.
Here’s a glance at the company’s steady growth in revenue per employee (RPE):
Meanwhile, research and development (R&D) costs decreased.
For the three- and nine-month periods ending September 30, 2024, R&D expenses totaled $10.4 million and $35.3 million.
This marks a significant reduction compared to $14.9 million and $68.4 million during the same periods in 2023, representing decreases of 30% and 48% respectively.
ESPR is still a tiny company with a $660 million market cap.
While small companies tend to be riskier, they can also produce the biggest gains.
Trading at a price-to-sales (P/S) multiple of 1.6X, ESPR looks cheap!
Especially considering that it nearly doubled its cash position to $145 million while demonstrating impressive revenue growth, alongside successful cost reductions.
Finally Seeing Double Digits 🤑
In March, we added ESPR to our Diamond Tier model portfolio.
After being in the red, we’re now up 20%!
We believe investors will drive the stock price even higher, so we’ll hold on to our position.
To get in on the ground floor of biotech — including exclusive portfolio insights across sectors and trade recommendations — click here to get exposure!
#GBC100: Tuesday, December 3, 2024
The #GBC100 is down 0.17% today.
Created on September 22, 2022, the #GBC100 is an index/portfolio comprised of opportunity, growth, innovation, and crypto-related investments.
Our goals with the #GBC100 are twofold . . .
First, we want readers to get a sense of what our investments are doing in the market, because they can sometimes perform very differently than traditional indices (like the S&P 500 or Nasdaq 100).
Second, we’d like to eventually turn the #GBC100 into an ETF.
That way, instead of owning hundreds of growth stocks, you can get exposure to ATG Digital thinking — in opportunity, growth, innovation, and crypto — all in one place.
To learn more or to express your support for the launch of an ETF (by completing a poll), click here.
Tomorrow: Dean will discuss a crypto miner we love. ⛏️ Stay tuned!
Right now, crypto is exploding . . . 💥
Bitcoin USD (BTC-USD) is making its way up to $100K, and XRP USD (XRP-USD) is leapfrogging. 🐸
So, what's going on?
Paul addressed all of this today! For all the details, watch the video below. 👇
On Tuesday, December 3, 2024, we hope you subscribe to our YouTube channel for more content like this! ✨
❤️ This Substack was made — by US, for YOU — with love. ❤️
Questions? Concerns? 🤔 Look Below 👇
Have questions or trouble accessing your account? Please reach out to us at info@atgdigital.media or schedule a call, and our Customer Support team will be happy to help.
You can also check our FAQ page on our website for an up-to-date list of questions and answers. Your question may have been addressed there.
*Please be advised that customer support calls are limited to 15 minutes and will strictly cover your membership subscription and billing needs only. Any calls that are disrespectful in nature may be subject to immediate termination.
Join us, be #BOP 🚀, be #StrongHands 🙌, #GoATG! ️️❤️️
Disclaimer/Legal Stuff Written in Plain English
What you read/watch/hear is OPINION, not financial/investment advice. Treat it no different than when you read/watch/hear your favorite author/YouTuber/podcaster. Despite our best efforts, we get things wrong and make mistakes. Investing is risky. There is no guarantee you will make money. Your investments may lose value. That’s RISK. Past performance is no guarantee of future results. Employees, contractors, and owners of ATG Digital, LLC own/trade/transact in the stocks, options, and crypto that are the subject of our trade alerts, updates, reports, and commentaries. We cannot give you personalized financial advice because we are NOT financial advisors. It’s on you to decide how much/when/what to buy/sell based on YOUR financial needs, plans, and risk preferences. There are no guarantees. Loss of your capital is an outcome that you should evaluate carefully with a financial advisor before you trade, speculate, or invest. It's your money and your responsibility.
Just a matter of time for crypto. Cannot imagine it at a MILLION dollars even though I know the amazing possibilities. Paul on YouTube, WOW!